stoxline Quote Chart Rank Option Currency Glossary
  
BriaCell Therapeutics Corp. (BCTX)
5.43  0.08 (1.5%)    04-23 16:00
Open: 4.7
High: 5.75
Volume: 507,292
  
Pre. Close: 5.35
Low: 4.7
Market Cap: 20(M)
Technical analysis
2025-04-23 4:37:26 PM
Short term     
Mid term     
Targets 6-month :  6.71 1-year :  7.84
Resists First :  5.75 Second :  6.71
Pivot price 4.2
Supports First :  4.26 Second :  3.33
MAs MA(5) :  4.74 MA(20) :  4.11
MA(100) :  2.72 MA(250) :  1.71
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  74.1 D(3) :  60.7
RSI RSI(14): 66.7
52-week High :  7.86 Low :  0.34
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BCTX ] has closed Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 5.76 - 5.78 5.78 - 5.8
Low: 4.98 - 5 5 - 5.02
Close: 5.39 - 5.42 5.42 - 5.47
Company Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Headline News

Wed, 23 Apr 2025
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - TradingView

Wed, 23 Apr 2025
Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan

Tue, 22 Apr 2025
BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus

Tue, 22 Apr 2025
Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan

Wed, 16 Apr 2025
BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

Wed, 16 Apr 2025
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 4 (M)
Shares Float 3 (M)
Held by Insiders 12.9 (%)
Held by Institutions 14 (%)
Shares Short 188 (K)
Shares Short P.Month 202 (K)
Stock Financials
EPS -4.75
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.22
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -158.2 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -7.33
Qtrly Earnings Growth 0 %
Operating Cash Flow -22 (M)
Levered Free Cash Flow -11 (M)
Stock Valuations
PE Ratio -1.15
PEG Ratio 0
Price to Book value 4.45
Price to Sales 0
Price to Cash Flow -0.92
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android